Study of a new antibody plus chemotherapy for leptomeningeal metastasis
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination treatment for cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). It uses an antibody given directly into the spinal fluid along with a chemotherapy drug, with the goal of targeting the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid tumor and cancer cells found in your spinal fluid.
- You are between 21 and 75 years old and have normal organ function, including adequate blood cell counts.
- You do not have severe brain or nerve problems, such as severe brain swelling or very low consciousness.
- You do not have serious bleeding problems or uncontrolled infections like HIV or active hepatitis B or C.
- You have not used certain targeted therapies for leptomeningeal metastasis in the first month of treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.
This trial tests a combination of two drugs, pemetrexed and nivolumab, given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (non-squamous non-small cell) that has spread to the lining of the brain and has not responded to other treatments.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
This trial tests a chemotherapy drug given directly into the spinal fluid for people with HER2-negative breast cancer that has spread to the lining of the brain and spinal cord (called leptomeningeal metastasis). It may help when standard treatments have stopped working or caused too many side effects.
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
This trial tests a chemotherapy drug called thiotepa, given through a small device placed under the scalp (Ommaya reservoir) that delivers the drug directly into the spinal fluid. It is for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord and who have stopped responding to certain targeted therapies.
Hear when a new Leptomeningeal Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.